|
Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive
Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.
More... |
| All times are GMT -7. The time now is 08:40 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021